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Abbreviation List:
AD – Alzheimer’s disease
APP – amyloid precursor protein
A – amyloid beta
PS1 – presenilin 1
LTP – long-term potentiation
NA – numerical aperture
NMDG  - N-methyl-D-glucamine 
Ser - serine
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Abstract: 
One of the key knowledge gaps in the field of Alzheimer’s disease research is the 
lack of understanding of how amyloid beta and tau cooperate to cause 
neurodegeneration. We recently generated a mouse model (APP/PS1+Tau) that 
develops amyloid plaque pathology and expresses human tau in the absence of 
endogenous murine tau. These mice exhibit an age-related behavioural hyperactivity 
phenotype and transcriptional deficits which are ameliorated by tau transgene 
suppression. We hypothesized that these mice would also display memory and 
hippocampal synaptic plasticity deficits as has been reported for many plaque 
bearing mouse models which express endogenous mouse tau.  We observed that 
our APP/PS1+Tau model does not exhibit novel object memory or robust long-term 
potentiation deficits with age, whereas the parent APP/PS1 line with mouse tau did 
develop the expected deficits.  These data are important as they highlight potential 
functional differences between mouse and human tau and the need to use multiple 
models to fully understand Alzheimer’s disease pathogenesis and develop effective 
therapeutic strategies. 
Introduction:
Alzheimer’s disease (AD) is neuropathologically defined by brain atrophy and the 
accumulation of amyloid plaques and neurofibrillary tangles.  Amyloid pathology 
develops very early in the disease process, and rare disease-causing mutations all 
act through impacting amyloid beta (A) accumulation; however, tau accumulation in 
neurofibrillary tangles is more closely associated with neurodegeneration and 
dementia symptoms. These data led to the theory that A initiates the disease 
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process causing downstream changes in tau that lead to neurodegeneration (Hardy 
& Higgins, 1992).  
Soluble forms of A cause synaptic dysfunction and loss with deficits in long-
term potentiation (LTP) and plaque-associated synapse degeneration observed 
robustly across many model systems (Koffie et al., 2009, 2011; Li et al., 2009; Klein, 
2013; Spires-Jones & Hyman, 2014). Further, many mouse models that develop 
amyloid pathology due to expression of familal AD genes and those that express 
both amyloid and human mutant tau associated with human tauopathies develop 
spatial memory deficits as assessed by behavioural tests including the water maze 
and novel object recognition (Oddo et al., 2003; DaRocha-Souto et al., 2011; 
Masuda et al., 2016; Sasaguri et al., 2017). An OVID-Medline search for papers 
pubished between 1946 and June 2020 generated 56 results (search terms with the 
terms (Amyloid beta-Peptides OR Amyloid) AND (tau Proteins OR Tauopathies) 
AND Mice AND (Memory OR Long term potentiation)). Of these, the vast majority 
(43) were studies looking at interventions that changed memory or LTP in mouse 
models of AD, without examining the interplay of A and tau.  Only 3 of these papers 
specifically studied the interactions of these two pathological proteins in memory or 
LTP. First, in mice expressing APP with the arctic mutation and wild-type human tau, 
genetic reduction of -site APP cleaving enzyme (BACE) which lowered soluble A 
levels improved memory concomitant with a reduction in mislocalisation of tau to 
post synapses (Chabrier et al., 2012).  Secondly, brain slices from tau knockout mice 
do not exhibit LTP inhibition upon application of exogenous soluble A, indicating 
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interplay between A and tau in LTP phenotypes (Shipton et al., 2011). Third, in 
mice with amyloid pathology, tau knockout prevented spatial memory deficits 
(Roberson et al., 2007). Several more studies suggest that lowering endogenous 
mouse tau levels protects against other synaptic phenotypes in mice with plaques 
(Ittner et al., 2010; Vossel et al., 2010; Roberson et al., 2011; DeVos et al., 2018).  
However, many of these studies looking at interplay between A and tau in memory 
and synaptic plasticity are complicated by the presence of endogenous mouse tau, 
which is different from human tau and thus may have different functional properties. 
Recent data also indicate that the interplay between A and tau is more complex 
than a linear cascade and likely involves glia and neuron-glia interactions 
(Henstridge et al., 2019).
We recently developed a mouse model without endogenous mouse tau 
(MAPTnull) which expresses human familial AD mutant amyloid precursor protein 
(APP) and presenilin 1 (PS1) and reversibly expresses human tau (APP/PS1+Tau 
mice) (Pickett et al., 2019).  These mice develop plaques, increases in inflammatory 
gene expression, and decreses in synaptic gene expression, and an age-related 
hyperactivity phenotype (Pickett et al., 2019). In this study, we tested the hypothesis 
that these APP/PS1+Tau mice would exhibit synaptic plasticity and memory deficits 
at the age when we previously observed behavioural and transcriptional phenotypes.  
To do this, APP/PS1+Tau mice and APP/PS1 mice with endogenous mouse tau 
were tested for novel object recognition memory and LTP.




APP/PS1+Tau mice were bred as previously described (Pickett et al., 2019). Briefly, 
all mice in this colony had no endogenous mouse tau (homozygous 
MAPTnull,  FVB.Mapttm1(EGFP)Klt
 (Tucker et al., 2001)), and feeder lines expressed (1) human Swedish mutant 
amyloid precursor protein and presenilin 1 delta exon 9 under control of the Thy1 
promoter (B6C3-Tg(APPsw,PSEN1dE9)85DboMm, (Jankowsky et al., 2004)) and a 
tetracycline transactivator transgene downstream of a calcium calmodulin kinase II 
promotor (CKtTA, B6.Cg-(Camk2a-tTA)1/MmayDboJ (Yasuda & Mayford, 2006)) 
and (2) human 0N4R tau under the control of a dox-off tetracycline transactivator 
promotor (FVB-Tg(tetO-0N4R-MAPTwt)21221, (Hoover et al., 2010)).  The two 
feeder lines were crossed to generate 4 experimental genotypes all MAPTnull: 
control mice expressing neither transgene, mice expressing the APP/PS1 transgene 
only (APP/PS1), mice expressing the tau transgene only (Tau), and mice expressing 
both the APP/PS1 and tau transgenes (APP/PS1+Tau).  One cohort of 
APP/PS1+Tau mice was tested for novel object recognition and open field behaviour 
at 3, 6, and 9 months of age with rotarod testing at 9 months.  This cohort was 
sacrificed at 9 months of age and some brains used for the LTP study. Another 
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cohort of littermates was tested for novel object recognition memory, open field 
behaviour, and rotarod at 10.5 and 14.5 months of age to ensure we had not tested 
mice too young to observe a memory phenotype. APP/PS1 and CKtTA mice with 
endogenous mouse tau and their littermate controls were also tested at 9-10 months 
of age. Supplemental tables 1-4 contain data from each mouse tested in these 
experiments.  Table 1 shows a summary of the mice used in this paper.
Animal work was carried out in accordance with the Animals [Scientific 
Procedures Act] 1986 (UK) and the council directive 2010/63EU of the European 
Parliament and the Council of 22 September 2010 on the protection of animals used 
for scientific purposes. 
Novel object recognition and open field testing
Animals were tested for novel object recognition in a square box (40 x 40 x 60 cm) 
made of dark opaque walls (laminated MDF) with approximately 2.5 cm of corn cob 
bedding on the floor of the arena. Animals were recorded using an overhead camera 
and the video signal was fed into Blackmagic Media Express computer software which 
captured the movement of the animals. Each day animals were brought into the testing 
room in their home cage upon the end of the 12 h dark cycle and allowed to settle for 
1 hour. Individual experiments were composed of 3 phases: habituation, sampling and 
probe, with all experiments performed in the morning. For habituation, animals were 
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exposed to the open field in the absence of any objects for 4 consecutive days. On 
day 1, animals were introduced to the centre of the arena along with cage mates for 
20 min. For days 2-4, individual animals were exposed to the arena for 10 min per 
day, being placed into the open field facing a different corner of the arena each day, 
the sequence of which was assigned using a random number generator. For each 
experimental group, the order in which animals were placed in the arena was randomly 
assigned using a random number generator.  On day 4 of habituation, open field 
exploration was recorded for 10 minutes using an overhead camera. These data were 
published previously  (Pickett et al., 2019); here the 9-10.5 month old data are shown 
in figure 1a for reference purposes.
Following habituation, individual mice participated in a sampling phase of 3 sampling 
trials and 1 probe trial. For the sampling phase (which took a total of 30 minutes per 
mouse), animals were exposed 3 times to 2 identical objects for 5 min followed by 5 
min in a holding cage (35 x 15 x 15 cm) that was identical to their home cages. The 
objects remained in the same location during sampling, in two opposing corners of the 
open field, each object put 10 cm from the corner. After the sampling phase animals 
were returned to their home cage. The bedding on the floor of the arena was mixed 
through to disperse odors, any waste material was removed, and objects were cleaned 
with alcohol between mice. Probe trials were conducted 24 h after sampling and 
consisted of a single 3 min exposure to 2 objects (1 familiar object from the sampling 
phase and 1 novel object, both objects placed at the locations objects occupied during 
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sampling), followed by 5 min in the holding cage prior to return to the home cage. 
Once all trials were completed each day, mice remained in the testing room for 1 h to 
rest prior to return to the holding room.
Over the course of an experiment each mouse participated three times in this task, 
with 1 day between iterations.  Each time, different objects were used.  In each probe 
trial we paired two objects that elicited comparable exploratory activity as determined 
in a previous study in naïve mice. This way we ensured that pre-existing object 
preferences did not bias behavior in the probe trials. The objects used in sampling and 
probe phases were counterbalanced across genotypes and repetitions of this task to 
ensure comparison between groups. Exploration was determined in a blind manner 
using in-house software (available upon reasonable request from corresponding 
author O.H.). Individual probe trials were manually scored, with exploration defined as 
a mouse being within 2 cm of an object, directing its nose at the object and being 
involved in active exploration such as sniffing or whisking. For each probe phase, a 
discrimination index (d) was calculated ((time exploring novel object – time exploring 
familiar object)/(time exploring both objects)). Mice are attracted to novelty, and values 
of d > 0, indicating that they prefer exploring the novel object, suggest that they have 
memory for the object encountered during sampling.  Values of d = 0 indicate mice 
treat both objects the same, and this absence of novelty preference suggests that they 
no longer express memory for the object encountered during sampling.  Probe trials 
in which a mouse did not reach at least 10 s of total exploratory activity of objects were 
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excluded from the analysis.  Effect size was calculated for wild-type mice with n=6 
showing a mean of 0.296, standard deviation of 0.145 and Cohen’s d effect size of 
2.041, indicating that groups of at least 6 have more than sufficient power to detect 
intact novel object recognition memory.  Group sizes for our experiments are outlined 
in Table 1.
Rotarod testing
To test motor function, mice were tested with a Rotarod (IITC Life Science) for 4 
consecutive days. Each day animals were brought into the testing room in their home 
cage and allowed to settle for 1 h. Animals were placed on the Rotarod in separate 
lanes with male and female mice running in separate trials. Each day, mice 
participated in 3 baseline trials and 7 training trials, no trial lasting longer than 90 s. 
Baseline trials consisted of 3 trials separated by 2-min long rests between trials. During 
baseline trials, the drums rotated at a constant speed of 4 rotations per minute.  Thirty 
minutes after the baseline trials, mice underwent 7 experimental trials with 2-min long 
rests in between. During the training trials, the rotational speed of the drums 
accelerated, from a starting speed of 4 rotations per minute to a final speed of 25 
rotations per minute that was reached within 60 s. The average latency to fall off of 
the rotarod in experimental trials on the last day of testing was used to compare groups 
of genotypes. Data from mice who consistently jumped off of the rotarod (as opposed 
to running until they fell) were excluded from the analysis.
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Electrophysiology
Electrophysiology experiments were performed with the experimenter blind to 
genotype. Acute horizontal brain slices were prepared as follows. Mice were deeply 
anaesthetized by the inhalation of isoflurane followed by intra-peritoneal injection of 
pentobarbital (20%, 0.7l/g). Animals were transcardially perfused with oxygenated 
(95% O2, 5% CO2) protective NMDG-based solution of the following content (mM): 92  
N-methyl-D-glucamine (NMDG), 2.5 KCl, 1.25 NaH2PO4, 30 NaHCO3, 20 HEPES, 25 
glucose, 5 Na-ascorbate, 3 Na-pyruvate, 0.5 CaCl2, and 10 MgCl2, pH  7.3–7.4 (titrated 
with 5M HCl). The mouse was decapitated and the brain was quickly dissected and 
placed into room temperature oxygenated (95% O2-5% CO2) NMDG-based solution. 
Frontal lobe area and cerebellum were removed from the brain. Left hemisphere of 
the brain was mounted on the stage of a Vibrating Microtome 7000 (Campden 
Instruments LTD, England, UK) and the first 3-4 hippocampal slices (400 μm) from the 
dorsal part of the hemisphere were cut at horizontal plane. During recovery period 
freshly prepared slices were incubated at 34°C for 12 min in oxygenated NMDG 
solution. After that slices were transferred to submerged type storage chamber and 
maintained at a room temperature for at least 2 h before use in an oxygenated artificial 
cerebrospinal fluid (ACSF) of the following composition (mM): 119 NaCl, 3 KCl, 2.0 
CaCl2, 1.3 MgSO4, 1.2 NaH2PO4, 26 NaHCO3 and 11 glucose, pH 7.35.
Slices were transferred to the interface type recording chamber and perfused with 
oxygenated ACSF (1.5-2 mL/min). The temperature in the chamber was maintained at 
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25-26°C (PTC03, Scientific Systems Design, Ontario, Canada). Extracellular field 
excitatory postsynaptic potential (fEPSP) recordings were obtained from the 
hippocampal CA1 stratum radiatum using Differential AC Amplifier 1700 (A-M 
Systems, Carlsborg, WA, USA). The recording electrode was an Ag/AgCl wire in 
ACSF-filled extracellular glass microelectrode (1-1.5 MΩ). Evoked postsynaptic 
responses were elicited by stimulation of Schaffer collaterals using a bipolar 
stimulating electrode and DS3 Isolated current stimulator (Digitimer Ltd, Hertfordshire, 
UK). Synaptic response profiles were determined by generating input–output curve 
(stimulation intensity between 10 and 100  μA, 100 μs) for each slice. No significant 
differences were found in the input-output curve between genotypes. The input-output 
profile of the slice was used to set the stimulation strength for long term potentiation 
(LTP) experiments. For LTP experiments, the stimulation intensity was set to elicit 
30% of maximal fEPSP slope. This resulted in different absolute stimulus intensity 
between slices and animals; however, this paradigm ensured that the recruitment of 
synapses was standardised relative to the overall excitability of the slice. Data were 
normalized to pre-tetanus for all groups which also controls for stimulus intensity 
differences.  For pre- and post-tetanus stimulation, the stimulation was applied every 
30 s. After 10-20 min of stable baseline recording high-frequency tetanic stimulation 
(HFS, 100 Hz, 1 s) was delivered. Data was amplified x100, band-pass filtered (1Hz – 
5kHz) and digitized at 20.8 or 20.06kHz using an analogue-to-digital converter 
(National Instruments, Austin, TX) and acquired using WinWCP (Strathclyde 
Electrophysiology Software, Glasgow, UK).
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Offline data analysis was performed using ClampFit (Axon Instruments, USA). The 
fEPSP slope was calculated between 2 manually positioned cursors. The first cursor 
was positioned at the rising inflection of the fEPSP after the fiber volley. The second 
cursor was set to measure the slope of monosynaptic EPSP, and placed before the 
point where the rising slope began levelling off, to exclude population spikes. 
Immunohistochemistry 
For immunohistochemical analysis, mice were sacrificed by terminal anesthesia at 9 
months of age after completing behavioural tests.  The animals were perfused with 
phosphate buffer saline, brains were dissected, and one hemisphere fixed for 48 hours 
in 4% paraformaldehyde with 15% glycerol cryoprotectant.  The other hemisphere had 
tissue from entorhinal cortex and hippocampus prepared for array tomography as 
described previously (Kay et al., 2013; Pickett et al., 2019). Coronal sections, 50 m 
in thickness, were cut through the entire fixed hemisphere. Every 20th section from 
n=5 mice per group was stained with pan A antibody AW7 (a generous gift from Prof 
Dominic Walsh) and plaque fibrils counterstained with 0.05% Thioflavin S in 50% 
ethanol. Images were acquired on a Zeiss AxioImager microscope with a 20x 
objective. For array tomography, embedded tissue blocks were sectioned with an 
ultracut microtome (Zeiss) into ribbons of 70nm serial sections. Ribbons were stained 
with primary antibodies at 1:50 dilution in blocking buffer AW7 (secondary - donkey 
anti rabbit 488, Invitrogen) one of the following tau antibodies: Total Tau (Gt, R&D 
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systems, secondary donkey anti goat 594, Invitrogen), PhF1 (a generous gift from 
Peter Davies, secondary donkey anti mouse 594, Invitrogen), Alz50 (from Peter 
Davies, secondary antibody donkey anti mouse IgM 594, Invitrogen), or CP13 (from 
Peter Davies, secondary antibody donkey anti mouse 594, Invitrogen).  After 
secondary antibody staining, nuclei were counterstained with DAPI, coverslips were 
mounted with ImmuMount, and images acquired on a Ziess AxioImager microscope 
with a 63x, 1.4NA objective.
Data analysis
Statistical analyses were performed and graphs generated in R Studio v1.2.1335 
running R package version 5.2.2. For novel object recognition discrimination ratios, 
each genotype was compared to the hypothetical discrimination ratio of d=0 using a 
one-sample t-test. P values were corrected for multiple comparisons with a Holm 
adjustment. Data were checked for normality with  Shapiro-Wilks normality tests.  To 
examine differences between genotypes and look for sex effects in the APP/PS1+Tau 
line behavioural studies at 9-10.5 months of age, linear mixed effects models were 
used with the experimental batch as a random variable with the formula: 
lmer(Variable_of_Interest~Genotype+Sex+(1|testing_batch)). To examine effects of 
age on behavioural phenotypes in APP/PS1+Tau and control genotypes, a linear 
mixed effects model was used which accounted for 2 batches of testing and multiple 
measurements per animal as follows: 
lmer(Variable_of_Interest~Genotype*Age+Sex+(1|testing_batch)+(1|Mouse_ID)).
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Assumptions of the models were tested using visual inspection of the Q-Q plot of 
residuals. To test correlations between variables, Spearman’s rank correlations were 
performed followed by Holm adjustments for multiple comparisons. 
For LTP data, the average fEPSP slope during a 10 min period before LTP 
induction was taken as the baseline, and values were normalized to this value. 
Potentiation was measured between 50 to 60 min after HFS. To avoid 
pseudoreplication, a mean normalised fEPSP slope was calculated across slices per 
animal. This mean normalised fEPSP slope was used in statistical comparison 
between groups and in plotting the time course of LTP. Statistical analysis was carried 
out using R. Normality of fEPSP slope data was tested using a Shapiro-Wilk normality 
test. Two groups did not meet normality due to low sample size (APP/PS1+Tau, n=5) 
and the presence of a single outlier (Tau). For these groups, results from both 
parametric and non-parametric tests are reported for LTP testing. For between group 
comparisons, homogeneity of variances was tested using the Bartlett test (p>0.05). 
Results are reported as box and whisker plots showing each measured value 
as an individual data point alongside the median (centre line) 75th percentile (top of 
box) 25th percentile (bottom of box), largest value within 1.5 times interquartile range 
above 75th percentile (top whisker), smallest value within 1.5 times interquartile range 
below 25th percentile (bottom whisker). LTP data and line graphs show mean ± SEM, 
Scatter plots show individual data points and linear regression lines with 95% 
confidence intervals.
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Data accessibility
Data used in this manuscript are provided in supplemental tables associated with the 
paper. For detailed raw files (e.g. movies of mice doing novel object recognition), 
contact authors.
Results:
To test the hypothesis that memory was impaired in APP/PS1+Tau mice, novel 
object recognition memory was assessed in mice between 9 and 10.5 months of 
age, a time point when we previously observed a hyperactivity behavioural 
phenotype alongside transcriptional dysregulation ( Pickett et al., 2019). Fig1a shows 
that as previously reported, these APP/PS1+Tau mice move farther in the open field, 
a behavioural measure of hyperactivity (linear mixed effects model APP/PS1+Tau vs 
control p<0.001, full statistics in supplemental table 5). Mice are innately curious and 
prefer to explore novel over familiar objects. A discrimination ratio in novel object 
recognition testing above 0 indicates preference for the novel object reflecting 
memory of which object was previously explored. Novel object memory testing did 
not uphold our hypothesis as all 4 genotypes exhibited significant novel object 
recognition memory at this age (Figure 1b). For all groups, the discrimination ratio 
was significantly different from 0 as determined by one-sample t-tests. After Holm 
correction for multiple testing, the p values for each group were below 0.001 (please 
see supplemental table 6 for exact t-statistics and p-values). We used a linear mixed 
Page 66 of 79European Journal of Neuroscience
For Peer Review
effects model to determine whether there were differences between genotypes or 
any sex effects while taking into account the testing was run in 2 batches (with 
testing batch as a random variable in the model).  This model indicates there were 
no differences between genotypes in novel object recognition nor were there any 
differences between male and female mice (supplemental table 7 contains the 
results of the model). The total amount of time mice explored the objects (exploration 
time) was examined as differing exploration times could contribute to differences in 
memory.  Although all groups exhibited novel object recognition memory, there were 
significant differences between groups and between sexes in exploration time 
(Figure 1c).  A linear mixed effects model reveals that tau mice and APP/PS1+Tau 
mice explore significantly more than control mice and females explore more than 
males (supplemental table 8).  However, in our dataset, we do not see a correlation 
in any group between exploration time and novel object discrimination ratio (Figure 
1d, Spearman correlation p values >0.3 for all genotypes). Thus, in our mice, the 
different exploration times between groups is unlikely to affect novel object memory 
(for similar results see Akkerman et al., 2012).  Many previous studies have reported 
novel object recognition deficits in APP/PS1 at ages when plaque deposition was 
evident (Pedrós et al., 2014; Gu et al., 2016; Shen et al., 2017). We previously 
reported plaque deposition in these APP/PS1+Tau mice starting by 6 months of age 
(Pickett et al., 2019).  Further, we previously reported that A levels in the brain are 
approximately 15 pg/mg total protein and are not different between APP/PS1 and 
APP/PS1+Tau mice and tau protein levels are approximately 10 ng/mg total protein 
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and do not differ between APP/PS1+Tau mice and Tau mice (Pickett et al., 2019).  
Since both plaques and tangles have been associated in mice with spatial memory 
disruption, we stained for plaques and phosphorylated tau. We confirm in this study 
that both APP/PS1+Tau mice and littermate APP/PS1 mice at 9 months of age have 
substantial plaque deposition (Figure 1e,f). In the APP/PS1+Tau mice, there are 
small accumulations of phosphorylated tau around plaques, but no neurofibrillary 
tangle pathology as we previously reported (Figure 1f). High resolution array 
tomography imaging shows accumulation of small punctae of tau staining in multiple 
forms (1g), total tau, phosphoTau labelled with PHF1 and CP13 antibodies, and 
misfolded tau labelled with Alz50 antibody.  To determine whether the lack of novel 
object recognition in 9-10.5 month old APP/PS1+Tau mice was due to a delay in the 
phenotype compared to the parent APP/PS1 line with endogenous mouse tau, we 
completed an ageing study in these mice testing memory out to 14 months of age 
(Figure 1g,h). Two cohorts of mice were tested, one at 3, 6, and 9 months of age, 
and another at 10.5 and 14 months of age.  APP/PS1+Tau mice still have intact 
novel object recognition memory at 14 months of age (one-sided t-test adjusted p 
value = 0.023), and a linear mixed effects model reveals there is not a significant 
effect of genotype, age, or sex on memory (supplemental table 9). There are age 
and sex effects on exploration time, but no genotype effects (supplemental table 10). 
Rotarod testing was used to determine if there were motor deficits in this line. Subtle 
changes in latency to fall off the rotarod were observed between sexes and in tau 
mice compared to controls (Supplemental figure 1, supplemental table 11), however 
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these were likely to be driven by the CKtTA activator transgene as will be discussed 
later.
To determine whether the lack of memory phenotype in these mice was due to lack 
of endogenous mouse tau and to confirm that in our hands the novel object 
recognition test can detect memory deficits in an established model, we tested the 
parent APP/PS1 line from Jackson labs that have endogenous mouse tau. As 
expected, APP/PS1 mice with endogenous mouse tau had novel object recognition 
deficits at 9 months of age, with their discrimination ratios being not significantly 
different from zero (one-sample t-test adjusted p-value=0.489) whereas wild-type 
littermates had a significant preference for the novel object (one-sample t-test 
adjusted p-value=0.008, Figure 2a). This memory deficit was not due to differences 
in total time exploring the objects which were not different between the 2 groups 
(Figure 2b).  As observed in the APP/PS1+Tau line and littermate controls, there 
was also no correlation between novel object recognition and exploration time in 
APP/PS1 mice with endogenous mouse tau or their wild-type littermates (Spearman 
rank correlation adjusted p-value=1.000 for both groups, Figure 2c).  
As a further control, we examined novel object recognition memory in mice 
expressing only the CKtTA transactivator gene. This is important as this transgene is 
used in APP/PS1+Tau mice to drive human tau expression, and we previously 
observed this transgene affects brain weight in mice (Pickett et al., 2019). Here we 
observe that there was no effect of this transgene on novel object recognition. Both 
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CKtTA and littermate control mice have intact recognition memory (one-sample t-
tests adjusted p-value<0.05 for both groups Figure 2d) and there is no difference 
between genotypes or sexes (linear mixed effects model with testing batch as a 
random variable, Supplemental table 12). Compared to controls, there is no effect of 
this transgene or sex on exploration time in the CKtTA mice (linear mixed effects 
model with testing batch as a random variable, Supplemental Table 13, Figure 2e). 
There was also no correlation between novel object recognition discrimination ratio 
and exploration time (Spearman rank correlation adjusted p-value=1.000 for both 
groups,  Figure 2f). There was a significant rotarod deficit in CKtTA mice 
(supplemental figure 1, supplemental table 14), indicating that the driver transgene in 
the absence of tau expression is sufficient to cause a motor phenotype. However, 
this did not cause an impairment of the ability to explore objects nor did it cause 
memory deficits.
To assay hippocampal LTP, we tetanized the Schaffer collateral pathway. Intact LTP 
was observed in control, APP/PS1, and Tau genotypes at 9-10.5 months of age 
(Figure 3; Wilcoxon test baseline = 100% - control: 138%, IQR 41%, V=91, adjusted 
p=0.001; APP/PS1: 126%, IQR 12%, V=66, p=0.039; Tau: 137%, IQR 21%, V=45, 
p=0.016).  In APP/PS1+Tau mice at this age, although the EPSP slope 60 minutes 
after tetanisation was 122% of baseline, this did not reach significance (IQR 10%, 
V=15, p=0.06, adjusted p=0.25). However, we are hesitant to interpret this as a loss 
of LTP since there is no significant difference in the extent of potentiation between 
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genotypes in the APP/PS1+Tau cohort (Kruskall-Wallis Chi2(3)=1.72, p=0.63), and 
the lack of significance in the APP/PS1+Tau group may be driven by the smaller 
group size, a limitation of the number of animals available for experiments in this 
complex cross.
In WT mice with endogenous mouse tau, tetanization resulted in a significant 
potentiation of the fEPSP slope measured in CA1 stratum radiatum (129  ± 8.7% of 
baseline, t(5)=3.4, Holm adjusted p=0.04, 2-tailed, one-sample t-test compared to 
mean of 100%). In APP/PS1 littermates with endogenous mouse tau, the same 
stimulation paradigm did not induce significant potentiation (109.9 ± 7.1% of 
baseline, t(6)= 1.4, Holm adjusted p= 0.43 2-tailed, one-sample t-test compared to 
mean of 100%; Figure 3). Together, these data indicate that tau is needed to drive 
LTP deficits in APP/PS1 mice.
Discussion:
Understanding the cascade from early A accumulation through pathological tau 
accumulation to neural circuit dysfunction and neurodegeneration remains one of the 
key challenges facing the Alzheimer’s disease field (Karran et al., 2011; Mauricio et 
al., 2019), and  there are relatively few studies directly addressing the cooperation of 
A and tau in disrupting memory and synaptic plasticity.
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Our previous work in the APP/PS1+Tau mouse line and human postmortem tissue 
indicate that both A and tau accumulate in synapses, where it may contribute to 
synaptic dysfunction and downstream cognitive decline (Jackson et al., 2016, 2019; 
Zhou et al., 2017; McInnes et al., 2018; Hesse et al., 2019; Pickett et al., 2019).  
Similar to findings by Chabrier et al., 2012, who expressed mutant APP and wild-
type human tau, in the APP/PS1+Tau line, we observe tau accumulation in post 
synapses, which is associated with a behavioural hyperactivity phenotype (Pickett et 
al., 2019).  In contrast, we did not observe memory deficits in  APP/PS1+Tau mice . 
This discrepancy could reflect that the mice in Chabrier et al retained endogenous 
mouse tau in addition to expressing wild-type human tau, and mouse tau is known to 
be important for synaptic phenotypes induced by A (Roberson et al., 2011; Shipton 
et al., 2011).
Indeed, we confirm the importance of mouse tau driving A phenotypes in this study 
as we observe that APP/PS1 mice expressing endogenous mouse tau do exhibit 
both novel object memory and LTP deficits at 9-10.5 months of age as has been 
reported previously (Pedrós et al., 2014; Gu et al., 2016; Shen et al., 2017)(Cai et 
al., 2017; Wu et al., 2017). Whereas in agreement with previous reports indicating 
that lowering endogenous mouse tau protects APP overexpressing mice (Ittner et al., 
2010; Vossel et al., 2010; Roberson et al., 2011; Shipton et al., 2011; DeVos et al., 
2018), here we observe that APP/PS1 mice on a MAPTnull background do not have 
novel object recognition or LTP deficits compared to littermate controls.  
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Surprisingly, expression of human tau in these mice did not simply reconstitute the 
behaviour and plasticity deficits seen in APP/PS1 mice with mouse tau. These data 
indicate that the differences between mouse and human tau may be important in 
mediating the synaptotoxic effects of A Alternatively, the overexpression of human 
tau in our APP/PS1+Tau line with the CamKII promotor controlled CKtTA 
transactivator does not result in normal spatiotemporal expression of tau and has 
higher levels than endogenous mouse tau, which may affect the interactions with A.  
Either way, our results support the need for the use of multiple models alongside 
descriptive human tissue studies to ensure translational relevance of mouse studies 
in the Alzheimer’s field.
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Figure 1: APP/PS1+Tau mice have intact object recognition memory despite plaque 
deposition.  As previously reported (Pickett et al 2019), at 9-10.5 months of age, 
APP/PS1+Tau mice have a behavioural hyperactivity phenotype as they travel 
significantly farther than controls in the open field (a, * linear mixed effects model 
APP/PS1+Tau vs control p<0.0001).  At this same age, all four genotypes in the 
APP/PS1+Tau cross have discrimination ratios significantly different from zero 
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indicating intact object memory (b, * one-sample t-test p<0.001).  Exploration time 
differed between groups (c, * linear mixed effects model Tau vs control p=0.019).  
Performance in the novel object recognition test was unlikely affected by differences 
in exploration times as none of the groups exhibited a correlation between these 
measures (d, Spearman correlation each group p>0.3, linear regression lines shown 
alongside grey 95% confidence intervals). Staining with pan A antibody AW7 
(magenta), thioflavin S to label fibrils (cyan) and PHF1 phospho-tau antibody (yellow) 
shows plaques in hippocampus of both APP/PS1 and APP/PS1+Tau mice (e,f) and 
small accumulations of phospho-tau around plaques in APP/PS1+Tau mice (arrows, 
f). Higher resolution imaging with array tomography (g) reveals small accumulations 
of several forms of tau in APP/PS1+Tau mice: total tau, PHF1 positive tau 
phosphorylated at Ser396/404, CP13 positive tau phosphorylated at Ser202,and 
Alz50 positive misfolded tau. Examining averages of discrimination ratios per group 
over time (h) reveals that APP/PS1+Tau mice have intact object recognition memory 
up to 14 months of age (dotted line represents 2 different cohorts were tested at 3, 6, 
9 months and 10.5, 14 months).  Trajectories of individual mice are shown in (i).  
Individual mouse values are shown as points a-d with male mice indicated with 
circles and female mice with triangles. Numbers of mice per group are indicated over 
the boxes in box and whisker plots. Scale bar represents 100 microns in e,f, 10 
microns in g.  
Figure 2: APP/PS1 mice with endogenous mouse tau have deficits detecting in 
object memory assessed in a novel object recognition task at 9-10.5 months of age 
(a, one sided t-test null hypothesis zero, t-statistic=1.319, adjusted p-value=0.489), 
while their wild-type (wt) littermates express intact object memory as shown by a 
discrimination ratio significantly larger than zero (a, * one-sample t-test, t =5.003, 
adjusted p =0.0082). Exploration time was not different between wt and APP/PS1 
mice and there was no effect of sex (b, two-way ANOVA effect of genotype 
F[1,8]=1.876, p=0.208, effect of sex F[1,8]=0.426, p=0.532). Scatterplots with linear 
regression lines and 95% confidence intervals (shaded in grey) show no correlation 
between discrimination ratio and exploration time in either genotype (c).  The CKtTA 
driver transgene does not affect novel object recognition performance (d, * control 
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one-sample t-test, t =3.504, adjusted p =0.019; CKtTA t=3.230, adjusted p =0.0289) 
or exploration time (e) and there is no correlation between these variables. Points 
represent individual mice. Male mice are indicated with circles and female mice with 
triangles. n per group is shown above each box.
Figure 3:   LTP was induced with tetanization at time 0 (arrows).  In slices from the 
APP/PS1+Tau line cohort which lack endogenous mouse tau, all genotypes exhibit 
fEPSP slopes above baseline (a). At 50-60 minutes post-tetanization (b), control, 
APP/PS1, and tau mice exhibit significant potentiation but the APP/PS1+Tau group 
is not significantly different from baseline (* p<0.05 Wilcoxon test compared to 1.0 
with Holm corrected p values). No significant differences were found in the input-
output curve between genotypes (c). Representative traces for the APP/PS1+Tau 
cohort are shown in (d).  In APP/PS1 mice with endogenous mouse tau, LTP was 
impaired at 9-10 months of age, while wild-type littermates exhibited significant LTP 
(e, f, * Holm adjusted p=0.04, one-sample t-test compared to mean of 1.0).   Again, 
no significant differences were found in the input-output curve between genotypes 
(g). Representative traces for the APP/PS1 cohort are shown in (h).   Data shown in 
a and e are means +/- standard error. Scale bars represent 10ms, 0.5mV. Points in 
box plots represent individual mice, n per group is shown above each box.
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Figure 1: APP/PS1+Tau mice have intact object recognition memory despite plaque deposition.  As 
previously reported (Pickett et al 2019), at 9-10.5 months of age, APP/PS1+Tau mice have a behavioural 
hyperactivity phenotype as they travel significantly farther than controls in the open field (a, * linear mixed 
effects model APP/PS1+Tau vs control p<0.0001).  At this same age, all four genotypes in the APP/PS1+Tau 
cross have discrimination ratios significantly different from zero indicating intact object memory (b, * one-
sample t-test p<0.001).  Exploration time differed between groups (c, * linear mixed effects model Tau vs 
control p=0.019).  Performance in the novel object recognition test was unlikely affected by differences in 
exploration times as none of the groups exhibited a correlation between these measures (d, Spearman 
correlation each group p>0.3, linear regression lines shown alongside grey 95% confidence intervals). 
Staining with pan A antibody AW7 (magenta), thioflavin S to label fibrils (cyan) and PHF1 phospho-tau 
antibody (yellow) shows plaques in hippocampus of both APP/PS1 and APP/PS1+Tau mice (e,f) and small 
accumulations of phospho-tau around plaques in APP/PS1+Tau mice (arrows, f). Higher resolution imaging 
with array tomography (g) reveals small accumulations of several forms of tau in APP/PS1+Tau mice: total 
tau, PHF1 positive tau phosphorylated at Ser396/404, CP13 positive tau phosphorylated at Ser202,and 
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Alz50 positive misfolded tau. Examining averages of discrimination ratios per group over time (h) reveals 
that APP/PS1+Tau mice have intact object recognition memory up to 14 months of age (dotted line 
represents 2 different cohorts were tested at 3, 6, 9 months and 10.5, 14 months).  Trajectories of 
individual mice are shown in (i).  Individual mouse values are shown as points a-d with male mice indicated 
with circles and female mice with triangles. Numbers of mice per group are indicated over the boxes in box 
and whisker plots. Scale bar represents 100 microns in e,f, 10 microns in g.   
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Figure 2: APP/PS1 mice with endogenous mouse tau have deficits detecting in object memory assessed in a 
novel object recognition task at 9-10.5 months of age (a, one sided t-test null hypothesis zero, t-
statistic=1.319, adjusted p-value=0.489), while their wild-type (wt) littermates express intact object 
memory as shown by a discrimination ratio significantly larger than zero (a, * one-sample t-test, t =5.003, 
adjusted p =0.0082). Exploration time was not different between wt and APP/PS1 mice and there was no 
effect of sex (b, two-way ANOVA effect of genotype F[1,8]=1.876, p=0.208, effect of sex F[1,8]=0.426, 
p=0.532). Scatterplots with linear regression lines and 95% confidence intervals (shaded in grey) show no 
correlation between discrimination ratio and exploration time in either genotype (c).  The CKtTA driver 
transgene does not affect novel object recognition performance (d, * control one-sample t-test, t =3.504, 
adjusted p =0.019; CKtTA t=3.230, adjusted p =0.0289) or exploration time (e) and there is no correlation 
between these variables. Points represent individual mice. Male mice are indicated with circles and female 
mice with triangles. n per group is shown above each box. 
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Table 1: Summary of mice included in the study












m 30 (45.5%) 41 (59.4%) 31 (47.0%) 18 (36.0%) 120 (47.8%)
f 36 (54.5%) 28 (40.6%) 35 (53.0%) 32 (64.0%) 131 (52.2%)












m 10 (40.0%) 17 (60.7%) 11 (44.0%) 8 (36.4%) 46 (46.0%)
f 15 (60.0%) 11 (39.3%) 14 (56.0%) 14 (63.6%) 54 (54.0%)












m 6 (46.2%) 4 (36.4%) 5 (55.6%) 2 (40.0%) 17 (44.7%)
f 7 (53.8%) 7 (63.6%) 4 (44.4%) 3 (60.0%) 21 (55.3%)








m 5 (55.6%) 11 (91.7%) 16 (76.2%)
f 4 (44.4%) 1 (8.3%) 5 (23.8%)








m 5 (55.6%) 3 (33.3%) 8 (44.4%)
f 4 (44.4%) 6 (66.7%) 10 (55.6%)
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Supplemental figure 1: Rotarod testing indicates that the CKtTA driver transgene affects 
motor performance. In the APP/PS1+Tau line (a), there are significant differences in 
exploration time between Tau and control mice and APP/PS1+Tau and control mice (*, 
p<0.05 linear mixed effects model, supplemental table 11) and between male and female 
mice (p=0.003). This decrease in exploration time in the lines containing human tau is likely 
due not to tau expression but to the CKtTA activator transgene used to drive tau as in the 
parent CKtTA line (b), there is a significant decrease in CKtTA mice compared to controls (* 
b=14.006, t=2.325, p=0.0345) in the absence of human tau expression. In the APP/PS1 
parent line with endogenous mouse tau, there is no difference between rotarod 
performance in APP/PS1 mice and wild-type littermates (c, one-way ANOVA F[1,6]=0.921, 
p=0.374), indicating that the observed memory deficits were not due to alterations in gross 
motor skills. Note mice that jumped off of the rotarod instead of running until they fell were 
excluded from this analysis. This precluded analysis of sex effects in the APP/PS1 line. 
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Graphical Abstract Text
Tulloch et al observe memory and long-term potentiation deficits in the APP/PS1 mouse 
model of familial Alzheimer’s disease, which are prevented by genetic removal of 
endogenous mouse tau.  Expression of human tau in APP/PS1 mice with endogenous tau 
knockout does not reinstate the memory and plasticity deficits. These results highlight the 
importance of understanding differences between mouse and human tau in modelling 
Alzheimer’s disease.
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